Switch theme
Sign up to access all valuation multiples
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
1983
122
LTM Revenue $0.5M
LTM EBITDA n/a
$8.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Inovio Pharmaceuticals has a last 12-month revenue of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Inovio Pharmaceuticals achieved revenue of $0.8M and an EBITDA of -$130M.
Inovio Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inovio Pharmaceuticals valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $10.3M | $0.8M | $0.1M | $0.5M | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$271M | -$130M | n/a | n/a | XXX |
| EBITDA Margin | -2640% | -15672% | NaN% | 0% | XXX |
| Net Profit | -$304M | -$280M | -$135M | XXX | XXX |
| Net Margin | -2959% | -33632% | -101237% | XXX | XXX |
| Net Debt | n/a | n/a | $2.5M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Inovio Pharmaceuticals's stock price is $2.
Inovio Pharmaceuticals has current market cap of $80.9M, and EV of $8.5M.
See Inovio Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.5M | $80.9M | XXX | XXX | XXX | XXX | $-4.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Inovio Pharmaceuticals has market cap of $80.9M and EV of $8.5M.
Inovio Pharmaceuticals's trades at 17.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Inovio Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Inovio Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $8.5M | XXX | XXX | XXX |
| EV/Revenue | 63.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInovio Pharmaceuticals's NTM/LTM revenue growth is 1136%
Inovio Pharmaceuticals's revenue per employee for the last fiscal year averaged $7K, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Inovio Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Inovio Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Inovio Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -84% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $7K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5719% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10418% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 16137% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inovio Pharmaceuticals acquired XXX companies to date.
Last acquisition by Inovio Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Inovio Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Inovio Pharmaceuticals founded? | Inovio Pharmaceuticals was founded in 1983. |
| Where is Inovio Pharmaceuticals headquartered? | Inovio Pharmaceuticals is headquartered in United States of America. |
| How many employees does Inovio Pharmaceuticals have? | As of today, Inovio Pharmaceuticals has 122 employees. |
| Who is the CEO of Inovio Pharmaceuticals? | Inovio Pharmaceuticals's CEO is Dr. Jacqueline E. Shea. |
| Is Inovio Pharmaceuticals publicy listed? | Yes, Inovio Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Inovio Pharmaceuticals? | Inovio Pharmaceuticals trades under INO ticker. |
| When did Inovio Pharmaceuticals go public? | Inovio Pharmaceuticals went public in 1998. |
| Who are competitors of Inovio Pharmaceuticals? | Similar companies to Inovio Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Inovio Pharmaceuticals? | Inovio Pharmaceuticals's current market cap is $80.9M |
| What is the current revenue of Inovio Pharmaceuticals? | Inovio Pharmaceuticals's last 12-month revenue is $0.5M. |
| What is the current EV/Revenue multiple of Inovio Pharmaceuticals? | Current revenue multiple of Inovio Pharmaceuticals is 17.1x. |
| What is the current revenue growth of Inovio Pharmaceuticals? | Inovio Pharmaceuticals revenue growth between 2023 and 2024 was -84%. |
| Is Inovio Pharmaceuticals profitable? | Yes, Inovio Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
